Drug Profile
Research programme: clotrimazole analogues - Cyclacel Pharmaceuticals/Lorus
Alternative Names: CYC-381; NC-169; NC-219; NC-381; NC-393; NC-394; NC-407; NuChem compoundsLatest Information Update: 17 Feb 2010
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Cyclacel Pharmaceuticals
- Class Imidazoles
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Sep 2007 Preclinical development is ongoing
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 20 May 2005 This programme is still in active development